Samsung Display Co., Ltd.

Samsung Electronics Co., Ltd.

Abclon Inc.

Gc Cell Corporation

Kumho Tire Co., Inc.

Jong Seo Lee

Joon Hak Oh

Won-ki Hong

Kyu Tae Kim

Bong Kook Ko

Won Ki Hong

Sang Chul Lee

Joo-yeon Lee

Se Yong Kim

Tae Hee Lee

Young Ha Lee

In Sik Hwang

Ki Hyun Kim

Ha-Yun Kang

Beom Shik Kim

Seock-Hwan Kang

Jeongmin Kim

Sungyoo Cho

Eunji Choi

Hoyong Lim

Miyoung Jung

You-Sun Kim

Seung Mi Seo

Seock Hwan Kang

Hyung-Ju Seo

Hui Nam

Sang Hyun Lee

Jong Sung Bae

Seung-Won Park

Hak Sun Kim

Yung Kyung Park

Hyun Jong Lee

Hyung Ju Seo

Carl Erik Mathias Uhlen

You Bean Kim

Gi Chang Park

Do Hyoung Kwon

Joo Yeon Lee

Hak Oh Joon

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.

Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts. Therefore, a composition of the present disclosure can be very usefully used for combined administration with the trastuzumab antibody for the treatment of cancer, or for the treatment of cancer not treated with trastuzumab.

The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.

Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof

The present invention relates to a switch molecule for activating a chimeric antigen receptor effector cell, to a polypeptide or fusion protein binding thereto, and to a chimeric antigen receptor. (i) When a switch molecule of the present invention is used, in order to improve safety of a CAR-T cell, if severe toxicity appears, a switch molecule lacking a targeting moiety can be injected to adjust activation of the CAR-T cell. (ii) When an antigen is mutated, or in order to cure various carcinomas, instead of an existing switch molecule, a switch molecule targeting a new antigen generated due to the mutation or a switch molecule targeting a different tumor associated antigen (TAA) can be injected into a patient to cure cancer more effectively.

Switch molecule and switchable chimeric antigen receptor

A display device unit includes: a display device; and a sound element disposed at a side surface or a rear surface of the display device, where the sound element includes a vibration material layer which provides a sound based on an electric field applied therein, and a pair of electrodes which generates the electric field in the vibration material layer.

Display device unit

The present invention relates to: a novel antibody or an antigen-binding fragment thereof for use in the treatment of cancer by targeting B cell malignancies; a chimeric antigen receptor comprising the same; and uses thereof. The antibody of the present invention is an antibody specifically binding to CD19 highly expressed in cancer cells (particularly, blood cancer) and has very low homology compared to the CDR sequences of conventional CD19 target antibodies, and thus the sequence thereof is unique. In addition, cells expressing a chimeric antigen receptor comprising an anti-CD19 antibody or antigen-binding fragment of the present invention induce immune cell activity in response to a positive cell line expressing CD19, and thus can be usefully used as a therapeutic agent for CAR-immune cells.

Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof

An exemplary embodiment of the present inventive concept provides a display device including: a display unit including a plurality of pixels disposed on a display area; a display controller configured to control the display unit; a sensor including a plurality of first sensing electrodes and a plurality of second sensing electrodes disposed in the display area; and a sensor controller configured to recognize a touch of a user inputted into the sensor in a touch sensing mode and to recognize a fingerprint of the user inputted into the sensor in a fingerprint sensing mode, wherein the sensor controller changes a mode to the fingerprint sensing mode when no touch is inputted for a predetermined time period in the touch sensing mode and changes the mode to the touch sensing mode when authorization on a fingerprint inputted into the sensor is succeeded in the fingerprint sensing mode.

Display device and driving method thereof

The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19.

Disclosed is a display module including a transparent display panel and a frame to fix a side of the transparent display panel, wherein the frame has a communication unit to receive data from the outside, a controller to process the received data and to output a drive command corresponding to the processed data and a display drive unit to drive the transparent display panel in response to the drive command from the controller. A display system includes a system body and a display module detachably mounted in the system body.

Display module and display system

A display device includes: a display panel configured to display an image; a sound element on a rear side of the display panel; and a rear chassis configured to receive the display panel and protect the rear side of the display panel, and including a protruding portion protruding away from the rear side of the display panel and corresponding to the sound element. The sound element includes a pair of electrodes, and a vibration material layer between the electrodes.

Display device

The present invention replaces an amino acid residue of a specific region of a parent antibody so as to improve the stability of the antibody, thereby improving druggability. A variant antibody of the present invention, compared to a parent antibody hz1E11, has significantly improved stability while having nearly the same productivity and efficacy. Therefore, the variant antibody of the present invention exhibits, in the development of HER2-specific antibodies, excellent characteristics such as reduction in production costs, inhibition of efficacy reduction and reduction of side effects.

Antibody having improved stability and specifically binding to HER2

The present disclosure relates to a touch sensor and a method for sensing a touch using the same, the touch sensor including a substrate, a first sensor and a plurality of second sensors provided on the substrate and configured to sense a location and a force of a touch, wherein the first sensor is disposed in a central area of one surface of the substrate, the plurality of second sensors are arranged to surround the first sensor, and a width of the plurality of second sensors increases as a distance from the central area increases.

Touch sensor and method for sensing touch using thereof

Growing community of inventors

Yongin-si, South Korea

Jong Seo Lee